Applied Therapeutics Inc
NASDAQ:APLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Applied Therapeutics Inc
NASDAQ:APLT
|
US |
|
IRB Brasil Resseguros SA
BOVESPA:IRBR3
|
BR |
|
S
|
Shandong Weigao Blood Purification Products Co Ltd
SSE:603014
|
CN |
|
T
|
Tan Phu Viet Nam JSC
VN:TPP
|
VN |
|
L
|
L'Oreal SA
XETRA:LOR
|
FR |
|
Ceapro Inc
XTSX:CZO
|
CA |
|
T
|
TAG Immobilien AG
XETRA:TEG
|
DE |
|
Kaisun Holdings Ltd
HKEX:8203
|
HK |
|
Kanzhun Ltd
NASDAQ:BZ
|
CN |
|
G
|
Guobang Pharma Ltd
SSE:605507
|
CN |
|
L
|
Life Healthcare Group Ltd
HKEX:928
|
HK |
|
R
|
Resolute Forest Products Inc
TSX:RFP
|
CA |
|
W
|
Wuxi Unicomp Technology Co Ltd
SSE:688531
|
CN |
|
T
|
Tianyu Digital Technology Dalian Group Co Ltd
SZSE:002354
|
CN |
|
G
|
GenNBio Inc
KOSDAQ:072520
|
KR |
Applied Therapeutics Inc
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
Applied Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2019-05-09. The Company’s molecular target is aldose reductase (AR), an enzyme that converts glucose to sorbitol under oxidative stress conditions. Its product candidates include AT-007, AT-001, AT-003 and AT-104. The Company’s AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. AT-001 is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), fatal fibrosis of the heart. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR). AT-104 is a dual selective PI3K inhibitor in preclinical development for T Cell Acute Lymphoblastic Leukemia (T-ALL).
